Monday, 04 April 2016 16:55

Eculizumab in children with hemolytic uremic syndrome

By  Kavanagh and Smith-Jackson
Rate this item
(0 votes)

Greenbaum et al. report the first prospective trial of eculizumab in pediatric atypical hemolytic uremic syndrome. As in adult trials, eculizumab appears effective and no serious safety signals were reported. There is the first suggestion of a dichotomy in response to treatment with a trend toward poorer outcome in those without complement abnormalities. This group, however, had worse renal function at presentation, and it remains to be seen whether this represents true non-response or merely late presentation.


Authors: David Kavanagh, Kate Smith-Jackson

Reference: Kidney Int Volume 89, Issue 3, March 2016, Pages 537-538; doi:10.1016/j.kint.2015.12.039

Additional Info

  • Language: English
  • Contains Audio: No
  • Content Type: Articles
  • Source: KI
  • Year: 2016
  • Members Only: No
Read 2162 times

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact


Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact